Couldn't have said it better ourselves... we are very excited about Biognosys' #NULISA offering and look forward to all the amazing data to come!
Ready to push the boundaries of #biomarker discovery & quantification? Discover how our #TrueDiscovery® plasma profiling and #NULISAseq™ multiplex targeted assay services can enhance your biopharma research and clinical trials. 🔍💡 The NULISAseq™ targeted CNS Disease 120 and Inflammation 250 panels are designed to detect low-abundance biomarkers like cytokines and chemokines from plasma and biofluids. These ultra-sensitive assays, available from our state-of-the-art facility in Switzerland, provide deep insights into hard-to-measure biomarkers within complex neurological and inflammatory pathways. 🧠⚙️ Know more: https://lnkd.in/dWCfa-87 #BiomarkerDiscovery #CNSResearch #InflammationResearch